N-acetylcysteine to Prevent Renal Failure

• Status: Unknown status
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the possible effect nephroprotective of N-acetylcysteine in patients with chronic kidney disease undergoing elective coronary artery bypass grafting by serial evaluation of renal function and to evaluate whether treatment reduces cardiac mortality, cardiac events and Global mortality, if it interferes with oxidative stress and inflammation and the need for dialysis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto do Coracao
• Collaborator: Fundação de Amparo à Pesquisa do Estado de São Paulo
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• adult patients aged 30 to 80 years old of both sexes

• indicated for elective CABG

• with glomerular filtration rate, assessed with the MDRD <60 mL/min/1, 73 m2 and> 15 mL / min / 1.73 m2 body surface

Exclusion Criteria:

• patients on chronic dialysis or with creatinine> 5 mg / dL preoperatively; individuals allergic or intolerant to N-acetylcysteine

• pregnant women

• patients with cancer

• patients underwent re-surgery within the first 72 hours postoperatively